Rosiglitazone reduces diabetes angiopathy by inhibiting mitochondrial dysfunction dependent on regulating HSP22 expression

The effects of rosiglitazone (RSG) in patients with type 2 diabetes mellitus (T2DM) remain controversial. Here, we first used network pharmacology to identify the common targets of RSG in the treatment of diabetes angiopathy (DA). Enrichment analysis found that the common genes were involved in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Lingling, Chen, Shengsong, Liang, Qian, Huang, Chahua, Zhang, Weifang, Hu, Longlong, Yu, Yun, Liu, Liang, Cheng, Xiaoshu, Bao, Huihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031002/
https://www.ncbi.nlm.nih.gov/pubmed/36968091
http://dx.doi.org/10.1016/j.isci.2023.106194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031002/
https://www.ncbi.nlm.nih.gov/pubmed/36968091
http://dx.doi.org/10.1016/j.isci.2023.106194

Ejemplares similares